The latter point is central, since targeting MEK5/ERK5 signalling, alone or in combination with chemotherapeutics or targeted drugs, is increasingly being considered as a possible treatment for cancer and inflammatory diseases [5]. This evidence concerns the gene MAP2K5 and cancer.